Contents

Search

remdesivir analogue VV116

Indications: - oral treatment of Covid-19 * prelimary results suggest efficacy similar to Paxlovid Dosage: - 600 mg PO every 12 hours on day 1 - 300 mg PO every 12 hours on days 2 through 5 Adverse effects: - dysgeusia (3.6% vs 25% with Paxlovid) - hypertriglyceridemia (11% vs 21% with Paxlovid) - hyperlipidemia (3.1% vs 9.6% with with Paxlovid) Mechanism of action: - deuterated remdesivir hydrobromide

General

antiviral agent

References

  1. Cao Z, Gao H, Bao H et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19. N Engl J Med 2022 Dec 28; [e-pub] PMID: 36577095 PMCID: PMC9812289 Free PMC article https://www.nejm.org/doi/10.1056/NEJMoa2208822